Ally Bridge Group
VC Fund
Hong Kong, Hong Kong
Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing. Ally Bridge Group focuses on both private and public equity investments, with a particular emphasis on pioneering life sciences companies and technologies. The firm is dedicated to bridging the gap betweengroundbreaking healthcare innovations and global markets. By leveraging its expertise and extensive network, Ally Bridge Group supports the growth and development of its portfolio companies. Its investment strategy is centered on transformative technologies and solutions that address major unmet medical needs.
- Total investments:
- 126
- Last investment:
- Lead investor:
- 44%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Ally Bridge Group invests in
Stages Ally Bridge Group invests in
Countries Ally Bridge Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 59 (47%)
- Health Care 53 (42%)
- Medical 20 (16%)
- Therapeutics 20 (16%)
- Medical Device 20 (16%)
Stage
- Series C 16 (13%)
- Post-IPO Equity 16 (13%)
- Series B 14 (11%)
- Series D 12 (10%)
- Series A 10 (8%)
Country
- United States 57 (45%)
- China 10 (8%)
- Canada 3 (2%)
- Israel 2 (2%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Steven Plachtyna
Vice President
|
Vice President | Total investments: 3 | Find email | |
|
Arthur Kuan
Founding Member
|
Founding Member | Total investments: 0 | Find email | |
|
David Nikodem
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Dayu Teng
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Frank Yu
Founder and CEO
|
Founder and CEO | Total investments: 23 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ensysce Biosciences develops oral drug delivery technologies targeting opioid misuse and overdose. Its Trypsin-Activated Abuse Protection (TAAP™) platform activates medications only upon ingestion, minimizing abuse through non-oral routes. The Multi-Pill Abuse Resistance (MPAR®) system adds a safeguard against overdose by inhibiting drug activationwhen excessive doses are consumed. These platforms are applied to treatments for severe pain and opioid use disorder, including PF614 and PF9001. Ensysce's approach has received recognition from the FDA, with TAAP™ designated as a Fast Track development and MPAR® as a Breakthrough Therapy. The company is also exploring the use of nafamostat, a component of its overdose protection products, for treating infections and pulmonary diseases. Its pipeline includes clinical and preclinical programs focused on enhancing the safety of prescription medications. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. | $21.5M / Post-IPO Equity / Aug 06, 2026 | ||
| Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M / Post-IPO Equity / Apr 28, 2026 | ||
| Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today. Founded in 2016, Calyxo is led by executives and investors with a strong track record of commercializing paradigm-shifting solutions in thefield of urology. Our team features some of the most talented, high-achieving and brightest minds in the medical device industry who are compelled by a desire to make a difference in kidney stone care. We are proud of our collaborative, diverse, fun and dynamic culture. | $40M / Series F / Apr 14, 2026 | ||
| Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M / Convertible Note / Mar 17, 2026 | ||
| Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M / Post-IPO Equity / Mar 17, 2026 | ||
| Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them. | $175M / Post-IPO Equity / Feb 02, 2026 | ||
| ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).It was founded in 2004 and headquartered in Toronto,Canada. | $75M / Post-IPO Equity / Jan 30, 2026 | ||
| Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $50M / Series B / Dec 30, 2025 | ||
| Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | ||
| Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M / Post-IPO Equity / Oct 28, 2025 | ||
| See all 126 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ally Bridge Group invest in?
Ally Bridge Group invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Post-IPO Equity stage. Most of the 126 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ally Bridge Group?
Public channels for Ally Bridge Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ally Bridge Group?
The team at Ally Bridge Group includes Steven Plachtyna (Vice President), Arthur Kuan (Founding Member) and David Nikodem (Managing Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
